ReviewInternational journal of molecular sciences2022
Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- When Immunophenotype Is Not Identity: A Clinicopathological Review of Neuroendocrine Differentiation in Tumors of the Female Genital Tract.Diagnostics (Basel, Switzerland) · 2026Review
- Dual PI3K/AKT/mTOR and CDK4/6 inhibition suppresses survivin to overcome uterine dedifferentiated endometrial carcinoma.Cancer gene therapy · 2026Article
- Analysis of DNA mismatch repair and microsatellite instability in molecular typing of endometrial carcinoma.Discover oncology · 2026Article
- Histopathology Images-Based Deep Learning Prediction of Histological Types in Endometrial Cancer.Cancer medicine · 2026Article
- Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma.BMC cancer · 2025Article
- Beyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer.International journal of molecular sciences · 2025Review
- Article
- Exploring the Genetic and Clinical Landscape of Dedifferentiated Endometrioid Carcinoma.International journal of molecular sciences · 2025Article
- Case Report on Dedifferentiated Carcinoma of Endometrium and It's Histopathological Characteristics.Journal of obstetrics and gynaecology of India · 2025Article
- Synchronous primary cancers involving the endometrium and fallopian tube: A case report.CytoJournal · 2025Article
- Detailed report on the clinicopathological factors of patients with endometrial cancer in Japan: a JSOG gynecologic tumor registry-based study.Journal of gynecologic oncology · 2024Article
- Undifferentiated endometrial carcinoma diagnosed during perimenopausal hormone therapy: a case report and literature review.Frontiers in oncology · 2024Article
- Analysis of Prognostic Factors and Cancer-Specific Survival in Patients with Undifferentiated and Dedifferentiated Endometrial Carcinoma Undergoing Various Postoperative Adjuvant Therapies.Cancer management and research · 2024Article
- Dedifferentiated endometrial carcinoma metastasis to axillary lymph node: a case report.Journal of medical case reports · 2023Review
- Cutaneous Metastasis of Endometrial Cancer and Long-Term Survival: A Scoping Review and Our Experience.Diagnostics (Basel, Switzerland) · 2023Article
- Investigating novel biomarkers in uterine corpus endometrial carcinoma: in silico analysis and clinical specimens validation via RT-qPCR and immunohistochemistry.American journal of cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is one of the most common gynecologic cancers worldwide. There were 417,367 newly diagnosed cases and 97,370 deaths due to this disease worldwide in 2020. The incidence rates have increased over time, especially in countries with rapid socioeconomic transitions, and EC has been the most prevalent gynecologic malignancy in Taiwan since 2012. The new EC molecular classifications of The Cancer Genome Atlas (TCGA) Research Network include clear-cell carcinoma, serous carcinoma, and carcinosarcoma, while undifferentiated/dedifferentiated EC (UDEC) is not mentioned, and most previous clinical trials for EC have not included UDEC. UDEC is rare, has an aggressive growth pattern, tends to be diagnosed at an advanced stage, and is resistant to conventional chemotherapy. In this review, case series or case reports on the clinical features and genomic/epigenetic and expression profiles on UDEC data are summarized in order to identify potential molecular targets for current and future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.